Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy.

Drugs & aging - 1 Jun 2020

Romskaug Rita, Wyller Torgeir Bruun, Straand Jørund, Kersten Hege, Molden Espen

Abstract excerpt

BACKGROUND: Many drugs with dose-dependent effects on hemodynamic variables are metabolized by cytochrome P450 2D6 (CYP2D6). The aim of this study was to compare prescribed dosages and hemodynamic responses of such drugs in relation to pharmacogenetic variability in CYP2D6 metabolism among patients aged ≥ 70 years exposed to polypharmacy. MATERIALS AND METHODS: We included 173 patients with detailed information...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alleles
Share to Blood Pressure

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Dose-Response Relationship, Drug

Share to Genotype

Share to Heart Rate

Share to Hemodynamics

Source

Open in PubMed Open full text

Identifiers

PMID: 32346827
DOI: 10.1007/s40266-020-00763-0
PMCID: PMC7272489

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy.PMID 32346827Read ↗

CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.Semantic proximity Read ↗

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.Semantic proximity Read ↗

Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.Semantic proximity Read ↗

Evidence based drug dosing and pharmacotherapeutic recommendations per genotype.Semantic proximity Read ↗

CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.Semantic proximity Read ↗

CYP2D6 Genotype Information to Guide Pimozide Treatment in Adult and Pediatric PatientsSemantic proximity Read ↗

Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.Semantic proximity Read ↗

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.Semantic proximity Read ↗

The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.Semantic proximity Read ↗

Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?Semantic proximity Read ↗

Aripiprazole and CYP2D6: A retrospective cohort study evaluating the impact of phenotype on metabolic abnormalities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.